Novartis Sees Profit Gaining Despite Copycats for Top Drug.

Novartis AG anticipates a rise in profit this year despite facing competition from generic versions of its top-selling drug. The company's optimistic forecast, driven by new medicines, led to a 3% increase in its stock value. Novartis is navigating patent expiries for key drugs like Entresto, but remains confident in the growth potential of its new therapies. CEO Vas Narasimhan's strategic focus on specific disease areas has been well-received by investors, with the company consistently surpassing market expectations in both earnings and sales. [Extracted from the article]